Kircik Leon, Del Rosso James
Indiana University School of Medicine, Madison, IN, USA.
J Drugs Dermatol. 2007 Jul;6(7):718-22.
Atopic dermatitis (AD) is a chronic cyclical inflammatory skin disease that is increasing in incidence. Twenty percent of those affected with AD are infants and young children. Despite the development of newer nonsteroidal topical therapies, such as calcineurin inhibitors, topical corticosteroids remain the gold standard for the treatment of active eczematous disease and management of exacerbation due to established efficacy and safety with appropriate use. The xerotic, sensitive skin of AD patients mandates the use of nonirritating and nondrying topical vehicles. Recently, phase III clinical studies have demonstrated the safety and efficacy of a novel aqueous hydrogel vehicle for desonide delivery in mild to moderate AD, which is free of fragrances and surfactants. Corneometry and transepidermal water loss studies have demonstrated that this patented hydrogel vehicle alone offers advantages including moisturization and skin barrier enhancement, both of which are significant when treating eczematous and xerotic skin. Patient and physician preference surveys suggest that the novel properties of this vehicle may aid in patient compliance with AD therapy.
特应性皮炎（AD）是一种发病率不断上升的慢性周期性炎症性皮肤病。20%的AD患者为婴幼儿。尽管出现了更新的非甾体类局部治疗方法，如钙调神经磷酸酶抑制剂，但由于局部糖皮质激素在合理使用时具有既定的疗效和安全性，仍然是治疗活动性湿疹样疾病和控制病情加重的金标准。AD患者皮肤干燥、敏感，需要使用无刺激性、不干燥的局部用药载体。最近，III期临床研究证明了一种新型水性水凝胶载体在轻度至中度AD中递送地奈德的安全性和有效性，该载体不含香料和表面活性剂。角质层测量和经表皮水分流失研究表明，这种获得专利的水凝胶载体本身具有保湿和增强皮肤屏障等优势，这在治疗湿疹样和干燥皮肤时都非常重要。患者和医生偏好调查表明，这种载体的新特性可能有助于患者坚持AD治疗。
